LUNG CANCER

A phase 1b/2a trial is investigating the combination of bemcentinib with pembrolizumab and doublet chemotherapy in patients with first-line non–small cell lung cancer that harbors STK11 mutations.

Shared insight on a patient case of ALK+ non–small cell lung cancer with CNS metastasis and the role of brain MRIs in clinical practice.

Expert panelists open their discussion on ALK+ non–small cell lung cancer and reflect on the impact of CNS metastasis in this setting.

Delivering cancer care from the first diagnosis is a team approach. Each step affects downstream processes.

During a Targeted Oncology™ Case-Based Roundtable™ event, Joel Neal, MD, PhD, discussed what options physicians would choose when treating a patient with non–small cell lung cancer who tested positive for an EGFR exon 20 insertion.

Phase 2 findings support a phase 3 investigation of neoadjuvant SHR-1701 as combination therapy for untreated stage III unresectable non–small cell lung cancer.

The VENTANA PD-L1 Assay can now be used to detect PD-L1 expression in patients with non–small cell lung cancer to determine eligibility for treatment with cemiplimab.

The phase 3 KEYNOTE-641 of pembrolizumab, enzalutamide, and androgen deprivation therapy has been discontinued, and overall survival rates in the phase KEYNOTE-789 study of pembrolizumab, pemetrexed, platinum-based chemotherapy did not meet statistical significance.

With statistically significant and clinically meaningful event-free survival improvement in patients with stage II-IIIB Non–small cell lung cancer, could perioperative pembrolizumab in combination with chemotherapy become a new treatment option?

During a Targeted Oncology™ Case-Based Roundtable™ event, Anne S. Tsao discussed with participants

Edward B. Garon, MD, MS, discusses data from the phase 3 CANOPY-A study and what they mean for the future of canakinumab for patients with non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Edward S. Kim, MD, MBA, discussed the use of adjuvant therapies including chemotherapy and osimertinib in patients with non–small cell lung cancer.

In the third interview of this series, Edward B. Garon, MD, reviews the treatment landscape in non–small cell lung cancer, with a focus on immunotherapy and the recent approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy.

Wellmarker Bio’s novel therapeutic antibody WM-A1-3389 will be tested with Merck’s pembrolizumab in a phase 1b study of patients with non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jason Porter, MD, discussed the CheckMate 9LA and KEYNOTE-407 trials of chemotherapy combined with immunotherapy in patients with advanced squamous cell lung cancer.

In the third installment of this series, Edward B. Garon, MD, MS, gives a historical overview of first-line immunotherapy options for non–small cell lung cancer, discusses the recent FDA approval of durvalumab/tremelimumab in combination with platinum-based chemotherapy in the same setting, and assesses treatment and research goals in the field.

Joshua K. Sabari, MD, discusses his use of durvalumab in the frontline setting for the treatment of patients with small-cell lung cancer and where he sees the role for the treatment.

Mark Socinski, MD and Joshua Sabari, MD, share their insight for community oncologists who treat patients with KRASG12C-mutated NSCLC with CNS metastases.

Two experts discuss the potential role of using adagrasib and sotorasib in the front-line setting and how it might shift the treatment paradigm for patients with KRASG12C-mutated NSCLC with CNS metastases.

Drs Socinski and Sabari comment on the use of sotorasib in patients with KRASG12C-mutated NSCLC with brain metastases and review data from the CodeBreak 100 and CodeBreak 200 trials.

Mark Socinski, MD and Joshua Sabari, MD review the key efficacy data from the KRYSTAL 1b cohort and discusses strategies for managing adverse events seen with adagrasib.

Drs Socinski and Sabari discuss the emergence of the KRAS12C mutation, specifically in patients with CNS metastases and how this factors into their treatment decision.

Drs Socinski and Sabari explain the different types of testing methods commonly used in their clinical practice and share advice for community oncologists who are testing for biomarkers in their patients with NSCLC.

Closing out her discussion on PD-L1–high metastatic NSCLC, Marina Chiara Garassino, MD, looks toward future evolutions in the treatment paradigm.

Centering focus on the second-line setting of PD-L1–high metastatic NSCLC, a key opinion leader defines a potential role for chemoimmunotherapy,